SCENESSE

Serial Number 79229902
Registration 5724241
708

Registration Progress

Application Filed
Feb 13, 2018
Under Examination
Approved for Publication
Jan 29, 2019
Published for Opposition
Jan 29, 2019
Registered
Apr 16, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-04-16) (Grace Period Filing)
Due: Oct 16, 2025 Grace Period - 62 days
Original deadline was Apr 16, 2025 (overdue)

Trademark Image

SCENESSE

Basic Information

Serial Number
79229902
Registration Number
5724241
Filing Date
February 13, 2018
Registration Date
April 16, 2019
Published for Opposition
January 29, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
708
Status Date
Jul 14, 2025
Registration
Registered
Classes
005

Rights Holder

Clinuvel Pharmaceuticals Limited

99
Address
Level 11, 535 Bourke Street
Melbourne VIC 3000
AU

Ownership History

Clinuvel Pharmaceuticals Limited

Original Applicant
99
AU

Clinuvel Pharmaceuticals Limited

Owner at Publication
99
AU

Clinuvel Pharmaceuticals Limited

Original Registrant
99
Melbourne AU

Legal Representation

Attorney
Michelle P. Ciotola

USPTO Deadlines

Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-04-16)
Due Date
April 16, 2025
Grace Period Ends
October 16, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

34 events
Date Code Type Description Documents
Jul 14, 2025 C75P O REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. Loading...
Jul 14, 2025 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Jul 14, 2025 NA75 E NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED Loading...
Apr 16, 2025 ES75 I TEAS SECTION 71 & 15 RECEIVED Loading...
Apr 16, 2024 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Jul 2, 2020 RNWL P INTERNATIONAL REGISTRATION RENEWED Loading...
Nov 14, 2019 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB Loading...
Sep 13, 2019 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Aug 8, 2019 FIMP P FINAL DISPOSITION PROCESSED Loading...
Aug 8, 2019 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Jul 16, 2019 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 16, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Mar 1, 2019 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Jan 29, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 29, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 11, 2019 INNT P TOTAL INVALIDATION PROCESSED BY THE IB Loading...
Jan 9, 2019 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Jan 9, 2019 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Jan 9, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 26, 2018 ALIE A ASSIGNED TO LIE Loading...
Dec 5, 2018 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 4, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 3, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 3, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 29, 2018 RFNT P REFUSAL PROCESSED BY IB Loading...
Jun 7, 2018 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Jun 7, 2018 RFRR P REFUSAL PROCESSED BY MPU Loading...
Jun 1, 2018 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
May 31, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 29, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 14, 2018 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Apr 10, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 9, 2018 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
Apr 5, 2018 SDRC M SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for skin care and for treating skin and skin relating conditions and disorders; medicated sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; chemical and biological preparations, substances, reagents and compounds, namely, drug delivery agents consisting of compounds that facilitate the delivery of pharmaceuticals which are based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and pharmaceutical preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for use in dermatology, for skin care, for the treatment of skin disorders, for the protection of the dermis and epidermis used in the manufacture, delivery and storage of pharmaceuticals, drugs and diagnostic preparations

Classification

International Classes
005